InvestorsHub Logo
Followers 51
Posts 8983
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Tuesday, 07/19/2022 12:29:35 AM

Tuesday, July 19, 2022 12:29:35 AM

Post# of 13320
CAMBRIDGE, MA / ACCESSWIRE / July 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. Until now, children under six were the only age group not eligible for vaccination against COVID-19 in Australia.

https://investors.modernatx.com/news/news-details/2022/Therapeutic-Goods-Administration-Grants-Provisional-Approval-for-Modernas-COVID-19-Vaccine-in-Children-Aged-Six-Months-to-Five-Years/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News